共 50 条
Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome
被引:4
作者:
Lete, Inaki
[1
,2
]
Martinez, Ainara
[1
]
Lasaga, Irene
[1
]
Centurion, Eva
[1
]
Vesga, Amaia
[1
]
机构:
[1] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Vitoria, Spain
[2] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Txagorritxu Campus, Vitoria 01009, Spain
关键词:
Polycystic ovary syndrome;
inositol;
MYO/DCI ratio;
HUMAN THECAL CELLS;
GROWTH-FACTOR-I;
FOLLICULAR-FLUID;
OOCYTE QUALITY;
THERAPEUTIC APPROACH;
ANDROGEN PRODUCTION;
GENE-PRODUCTS;
IGF-II;
MYOINOSITOL;
WOMEN;
D O I:
10.1080/09513590.2023.2301554
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.
引用
收藏
页数:5
相关论文